Register to leave comments

  • News bot Sept. 24, 2025, 7:25 p.m.

    📋 AMICUS THERAPEUTICS, INC. (FOLD) - Regulatory Update

    Filing Date: 2022-05-10

    Accepted: 2022-05-10 16:01:28

    Event Type: Regulatory Update

    Event Details:

    Amicus Therapeutics Inc (FOLD) Announces Regulatory Update Amicus Therapeutics Inc (FOLD) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: • PDUFA Date: may 10, 2022 • PDUFA Review Period Extended • Applications: BLA (Biologics License Application), NDA (New Drug Application), MAA (Marketing Authorization Application) • Designations: Breakthrough Therapy • Regulatory Agencies: FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency) • Status: Approved, Rejected, Extended Review • Committee Actions: CHMP Opinion Clinical Development: • Phase 3 trial ongoing • Data expected in 2022
    • expected in late 2022

    🔬 Clinical Development Pipeline (AMICUS THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    E (migalastat) DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    D (migalastat) DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    C (migalastat) DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    B (migalastat) DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    A (migalastat) DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    [14C] AT1001 DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    Placebo capsule DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    Potable water OTHER Phase PHASE1 Fabry Disease ClinicalTrials.gov
    GR181413A/AT1001 capsule DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    GR181413A/AT1001 solution DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    oral migalastat HCl DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    IV placebo DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov
    IV migalastat HCl DRUG Phase PHASE1 Fabry Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Amicus Therapeutics Inc
    • CIK: 0001178879
    • Ticker Symbol: FOLD
    • Period End Date: 2022-05-10
    • Document Type: 8-K